EPS for Adverum Biotechnologies, Inc. (ADVM) Expected At $-0.31

August 9, 2018 - By Billy Entrekin

Analysts expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report $-0.31 EPS on August, 14.They anticipate $0.04 EPS change or 14.81 % from last quarter’s $-0.27 EPS. After having $-0.30 EPS previously, Adverum Biotechnologies, Inc.’s analysts see 3.33 % EPS growth. The stock increased 6.84% or $0.32 during the last trading session, reaching $5.07. About 198,077 shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 132.08% since August 9, 2017 and is uptrending. It has outperformed by 119.51% the S&P500.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $316.03 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Nasdaq.com which released: “Adverum Biotechnologies Announces Clinical Progress Across Gene Therapy Pipeline” on August 01, 2018. Also Nasdaq.com published the news titled: “Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update” on August 08, 2018. Nasdaq.com‘s news article titled: “Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications” with publication date: July 24, 2018 was also an interesting one.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.